[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342675-105":59,"doc-detail-342675-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","human-epidermal-growth-factor-receptor-2-expression-and-subsequent-dynamic-changes-in-patients-with-ovarian-cancer","Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer","","HER2-targeting drugs are increasingly applied to non-breast cancers, yet ovarian cancer has limited data on HER2 expression patterns. This retrospective single-institution study reviewed patients who underwent HER2 testing and evaluated clinical parameters (histology, BRCA status) together with immunohistochemistry timing and anatomical location, plus genomic profiles. Among 200 patients, 28% showed IHC 2+ and 6% showed 3+. HER2 3+ tumors were enriched in specific histologies and occurred exclusively in BRCA-wildtype, MMR-proficient, or PD-L1-low contexts, with 11 of 19 patients showing increased HER2 on later biopsies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/human-epidermal-growth-factor-receptor-2-expression-and-subsequent-dynamic-changes-in-patients-with-ovarian-cancer/342675/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/human-epidermal-growth-factor-receptor-2-expression-and-subsequent-dynamic-changes-in-patients-with-ovarian-cancer/342675.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was HER2 expression assessed in this ovarian cancer study?","Question",{"text":112,"@type":113},"HER2 status was evaluated using immunohistochemistry (IHC) on formalin-fixed paraffin-embedded tissue specimens. Clinical parameters and timing were recorded alongside IHC results.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What proportion of ovarian cancer patients showed HER2 2+ or 3+ expression scores?",{"text":117,"@type":113},"Among 200 patients, 28% exhibited HER2 expression score 2+ and 6% exhibited score 3+.",{"name":119,"@type":110,"acceptedAnswer":120},"Did HER2 expression change over time in patients with repeat biopsies?",{"text":121,"@type":113},"Yes. In patients who underwent multiple time-lagged biopsies, 11 of 19 showed increased HER2 expression in subsequent biopsies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342675,1791174699,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nHuman epidermal growth factor receptor‑2 expression and subsequent dynamic changes in patients with ovarian cancer  \nYoo‑Na Kim1, Yun Soo Chung1, Eunhyang Park2, Seung Tae Lee3 & Jung‑Yun Lee1*  \nHuman epidermal growth factor receptor‑2 (HER2)‑targeting drugs are increasingly being incorporated into therapeutic paradigms for non‑breast cancers, yet studies on HER2 expression in ovarian cancer (OC) are inadequate. Here, we studied the HER2 status and dynamic changes inOC by reviewing the records of patients who underwent HER2 testing at a single institution. Clinical parameters, including histology, BRCA status, and immunohistochemistry (IHC), were evaluated alongside HER2 expression, timing, and anatomical location. Among 200 patients, 28% and 6% exhibited expression scores of 2+ and 3+, respectively. HER2 3+ scores were observed in 23%, 11%, 9%, and 5% of mucinous, endometrioid, clear cell, and high‑grade serous tumors, respectively, and were exclusively identified in BRCA‑wildtype, mismatch repair‑proficient, or PD‑L1‑low‑expressing tumors. The TP53 mutation rate was low, whereas ARID1A, KRAS, and PIK3CA mutations were relatively more prevalent with HER2 scores of 2+ or 3+ than with 0 or 1+ . Four of the five tumors with an HER2 3+ score exhibited ERBB2 amplification. Among 19 patients who underwent multiple time‑ lagged biopsies, 11 showed increased HER2 expression in subsequent biopsies. Patients with HER2‑ overexpressing OC exhibited distinct histological, IHC, and genomic profiles. HER2‑targeting agents are potential options for BRCA‑wildtype patients, particularly as later lines of treatment.  \nOvarian cancer (OC) stands as one of the most fatal gynecological malignancies, posing challenges regarding early diagnosis and frequent relapses in response to first-line chemotherapy1,2. Consequently, the use of targeted therapy based on immunohistochemistry (IHC) or next-generation sequencing (NGS)-based profiling has been suggested3–5. Human epidermal growth factor receptor-2 (HER2), a proto-oncogene encoding a tyrosine kinase receptor, is one of the most extensively studied targets in breast cancer6–8. The exploration of HER2-targeted therapies beyond breast cancer has gained traction subsequent to their establishment as the standard of care for breast cancer9. Phase II trials involving early generation anti-HER2 molecules, such as trastuzumab and lapatinib, have demonstrated minimal response rates in heavily treated patients with OC 10, 11. In the recent National Cancer Institute Molecular Analysis for Therapy Choice trial involving trastuzumab emtansine treatment, three patients with OC exhibited stable disease for > 6 months12. Moreover, a phase II basket trial involving trastuzumab deruxtecan (T-Dxd) treatment in locally advanced or metastatic setting (DESTINY-PanTumor02) revealed an outstanding objective response rate (ORR) across multiple cancers. The response was particularly poignant among tumors with HER2 3+ scores, suggesting a potential for T-Dxd to serve as a tumor-agnostic biomarker-driven therapeutic option13.  \nDespite these advancements in HER2-targeted therapy, previous research on HER2 in the context of OC has primarily focused on their positivity rates and association with prognostic factors. Moreover, differences in specimen type14 and sampling timing, before and after exposure to neoadjuvant chemotherapy or targeted therapy15, have been reported. Regarding the correlation between HER2 expression and prognostic factors in OC, existing evidence suggests an association with poor histological grade, advanced stage, and shorter survival time16. However, the comparability of these trials across studies has been challenging owing to the limited number of patients and the aforementioned technical variations.  \n1Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, 5","cbCaigkbM27e9ZWJ","https://ap.wps.com/l/cbCaigkbM27e9ZWJ","pdf",2350468,"English","# Methods\n## Patient recruitment and sample acquisition\n## IHC","[{\"question\":\"How was HER2 expression assessed in this ovarian cancer study?\",\"answer\":\"HER2 status was evaluated using immunohistochemistry (IHC) on formalin-fixed paraffin-embedded tissue specimens. Clinical parameters and timing were recorded alongside IHC results.\"},{\"question\":\"What proportion of ovarian cancer patients showed HER2 2+ or 3+ expression scores?\",\"answer\":\"Among 200 patients, 28% exhibited HER2 expression score 2+ and 6% exhibited score 3+.\"},{\"question\":\"Did HER2 expression change over time in patients with repeat biopsies?\",\"answer\":\"Yes. In patients who underwent multiple time-lagged biopsies, 11 of 19 showed increased HER2 expression in subsequent biopsies.\"}]","Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer | PDF",1790047682,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3ed80ccbba73b4176bb987cc56f05e8.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/540f178f7cbb1497343f774486745eb4.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3f8a46c1c758aab4db93f1bb0948494.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1977c011888257da54b0c342026eca66.webp",980,1287]